COPD

No matter what reason a patient is in the intensive care unit (ICU) of a hospital every moment and medication they take matters in helping them recover. A recent study looked at what dose of systemic corticosteroids should be given to patients with chronic obstructive pulmonary disease (COPD) exacerbations during their time in critical care.

Study results published in the European Respiratory Journal show that rates of inflammatory bowel disease (IBD) incidence have significantly increased in individuals with asthma or chronic obstructive pulmonary disease (COPD).

About half of all adults afflicted with obstructive airway disease have symptoms overlapping with chronic obstructive pulmonary disease (COPD) and asthma. According to data presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, this makes the possibility of misdiagnosis and mistreatment more likely.

Stress management, practice relaxation, and light exercise for patients with chronic obstructive pulmonary disease (COPD) can improve both their mental and physical states, according to researchers from Duke University.

The seasonality of exacerbations imposes a considerable burden on COPD patients in terms of mortality and morbidity, and on health care systems responsible for patient care.

For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), the right treatment can make a world of difference in the management of their condition. A recent study looked at how effective inhaled budesonide and systemic methylprednisolone can be for those patients.

As part of the annual meeting of the American College of Chest Physicians new information was rolled out on the "Live Well" Campaign aimed at helping patients with COPD.

In a presentation delivered at CHEST 2014, Edward Kerwin, MD, discussed the safety and efficacy of the twice-daily COPD treatment SUN-101, a glycopyrrolate inhalation solution delivered via nebulizer.

Stephen Rennard, MD, and his team focused their study on the assessment of long-term efficacy and safety of aclidinium bromide 400µg BID, an approved treatment option for patients afflicted with moderate to severe COPD.

Richard ZuWallack, MD, a specialist in pulmonary rehabilitation from St. Francis Hospital and Medical Center in Hartford, CT, presented results from 2 studies highlighting lung function improvement in patients with chronic obstructive pulmonary disease (COPD).

Prenatal exposure to phthalates, a chemical commonly used in cosmetics, increases children's asthma risk, according to study results published in Environmental Health Perspectives.

Calculation and interpretation of the anion gap is extremely useful in the evaluation and treatment of the patient with metabolic acidosis. In this installment, we look at case examples involving patients with multiple sclerosis and urosepsis; COPD, diabetes, and renal failure; and type 1 diabetes.

Researchers report finding a correlation between adverse childhood experiences and chronic obstructive pulmonary disease (COPD) development, with a more pronounced association in women.

Study results show that a multifaceted pilot telehealth program designed to improve self-management among patients diagnosed with chronic obstructive pulmonary disease (COPD) was well received by patients.

Study results show many patients with chronic obstructive pulmonary disease (COPD) may experience cognitive deterioration that becomes more severe as their COPD worsens.

Airway inflammation, a common symptom among chronic obstructive pulmonary disease (COPD) patients, does not contribute to muscle atrophy and nutrient depletion, according to researchers at the University of Leicester.

Adherence is defined as conforming to the recommendations made by the provider with respect to timing, dosage, and frequency of medication taking, and following these recommendations is important for patients with multiple sclerosis (MS) to fully benefit from disease-modifying therapies (DMTs).

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the United States, and of the top 5 causes of death, it is the only one that increased in incidence between 2007 and 2010, and our understanding of how to assess, manage, and treat COPD has advanced significantly over the past decade.

A staggering portion of the homeless who are alcohol dependent began drinking as children and cited their drinking as the main cause of their homelessness.

The US Food and Drug Administration announced the approval of a new drug for the treatment of chronic obstructive pulmonary disease.

Agent Orange exposure several decades earlier may increase morbidity from various diseases, some of which have rarely been explored in previous epidemiologic studies.

The continuous use of macrolide antibiotics for prophylaxis is associated with a significant reduction in chronic obstructive pulmonary disease exacerbations.

Though chronic obstructive pulmonary disease (COPD) exacerbations remain a top cause of US hospitalizations, 62% of patients surveyed by the COPD Foundation did not know much about them, and 16% had no knowledge on flare-ups.

Patients with chronic obstructive pulmonary disease are twice as likely to develop mild cognitive impairment.

Combination treatment with a fixed dose of indacaterol and glycopyrronium bromide was associated with significant improvements in several measures of lung function and health status compared to placebo and tiotropium in treatment-naïve patients with COPD.

New research has uncovered increased rates of dementia, chronic obstructive pulmonary disease, and several other disorders in older adults with schizophrenia.

Subgroup analysis from four studies reveals treatment with a once-daily, fixed-dose combination of umeclidinium vilanterol improves lung function at 24 weeks for a broad range of patients with moderate to severe COPD.

Treatment with a fixed-dose combination of aclidinium 400 µg and formoterol 12 µg significantly improved bronchodilation in patients with moderate to severe COPD compared with aclidinium or formoterol monotherapy alone.

Study results presented at the 2014 American Thoracic Society International Conference show that treatment with rosuvastatin reduces markers of inflammation in patients with COPD after 12 weeks, but is not associated with improvements in measures of lung function.

Study results presented at the 2014 American Thoracic Society International Conference show that treatment with simvastatin did not decrease exacerbation rates or time to first exacerbation in patients with COPD.